Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP2 | P42575 | 1/20 | 0.43 |
| ▸ | CASP4 | P49662 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | CASP9 | P55211 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18685000 | 0.80 | CASP3 (0.43) | CASP3CASP1CASP2CASP4CASP7 | |
| SCHEMBL13162978 | 0.80 | KAT2B (0.56) | CARM1PRMT6KAT2B | |
| SCHEMBL7106481 | 0.80 | KAT2B (0.56) | CARM1PRMT6KAT2B | |
| SCHEMBL4443892 | 0.80 | KAT2B (0.56) | CARM1PRMT6KAT2B | |
| SCHEMBL4150800 | 0.76 | CASP3 (0.43) | CASP3CASP1CASP2CASP4CASP7 | |
| SCHEMBL4150796 | 0.76 | CTSL (0.48) | CASP3CASP1CASP2CASP4CASP7 | |
| SCHEMBL14626061 | 0.75 | RAB9A (0.51) | CARM1PRMT6KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL14591100 | 0.74 | RAB9A (0.47) | CASP3CASP1CASP2CASP4CASP7 | |
| SCHEMBL8068970 | 0.71 | CCR2 (0.44) | RAB9ASMN1; SMN2ACHE | |
| SCHEMBL8068975 | 0.71 | CCR2 (0.44) | RAB9ASMN1; SMN2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686366-B1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2004-02-03 | — | — | US | claimed |
| US-20030139427-A1 | Bicyclic pyrimidinyl derivatives and methods of use thereof | OSI PHARMACEUTICALS INC. | 2003-07-24 | — | — | US | claimed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-6878716-B1 | Compounds specific to adenosine A1 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| EP-1347980-A4 | COMPOUNDS SPECIFIC TO ADENOSINE-A1,-A2A, AND- A3-RECEPTOR AND USES THEREOF | OSI PHARM INC (US) | 2005-02-09 | — | — | EP | disclosed |
| US-6686366-B1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2004-02-03 | — | — | US | disclosed |
| US-6673802-B2 | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | OSI PHARMACEUTICALS, INC. | 2004-01-06 | — | — | US | disclosed |
| EP-1347980-A1 | COMPOUNDS SPECIFIC TO ADENOSINE-A1,-A2A, AND- A3-RECEPTOR AND USES THEREOF | OSI Pharmaceuticals, Inc. (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20030139427-A1 | Bicyclic pyrimidinyl derivatives and methods of use thereof | OSI PHARMACEUTICALS INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1246623-A4 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI PHARM INC (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030073708-A1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| EP-1246623-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI Pharmaceuticals, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2002057267-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020094974-A1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | disclosed |
| WO-2001039777-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1 A2A, AND A3 RECEPTORS AND USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073708-A1 | Compounds specific to adenosine A3 receptor and uses thereof | ADORA3, ADORA2A, ADORA1 | CASP3 1681/4885CASP1 3358/4885CASP2 3377/4885 |
| US-20030139427-A1 | Bicyclic pyrimidinyl derivatives and methods of use thereof | ADORA2A, ADORA3, ADORA1 | CASP3 2416/4885CASP1 2697/4885CASP2 3138/4885 |
| US-20020094974-A1 | Compounds specific to adenosine A3 receptor and uses thereof | ADORA3, ADORA2A, ADORA1 | CASP3 1681/4885CASP1 3358/4885CASP2 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.